Inhibikase Therapeutics, Inc. (IKT) — what the price could be worth

What Inhibikase Therapeutics, Inc. could be worth

Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.

Projections are part of Pro

Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Inhibikase Therapeutics, Inc. and every other company we cover.

Bull, base and bear side by side
Defaults from the company’s own record
Its own P/E quartiles, not a guess
Three, five or ten years out

See Pro

Try it first on NVDA, AAPL, META or NKE, where it is open to everyone.